CN109152752A - 一种金刚烷胺类化合物及其制备方法和用途 - Google Patents

一种金刚烷胺类化合物及其制备方法和用途 Download PDF

Info

Publication number
CN109152752A
CN109152752A CN201780027329.9A CN201780027329A CN109152752A CN 109152752 A CN109152752 A CN 109152752A CN 201780027329 A CN201780027329 A CN 201780027329A CN 109152752 A CN109152752 A CN 109152752A
Authority
CN
China
Prior art keywords
alkyl
aryl
compound
formula
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780027329.9A
Other languages
English (en)
Chinese (zh)
Inventor
何必飞
樊玉平
卢辉雄
刘光元
王仲清
罗忠华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Priority to CN202110652331.3A priority Critical patent/CN113336673A/zh
Publication of CN109152752A publication Critical patent/CN109152752A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201780027329.9A 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途 Pending CN109152752A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110652331.3A CN113336673A (zh) 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610300245.5 2016-05-07
CN201610300245 2016-05-07
PCT/CN2017/083129 WO2017193870A1 (en) 2016-05-07 2017-05-05 Memantine compounds and their preparation and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110652331.3A Division CN113336673A (zh) 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN109152752A true CN109152752A (zh) 2019-01-04

Family

ID=60266756

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780027329.9A Pending CN109152752A (zh) 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途
CN202110652331.3A Pending CN113336673A (zh) 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110652331.3A Pending CN113336673A (zh) 2016-05-07 2017-05-05 一种金刚烷胺类化合物及其制备方法和用途

Country Status (4)

Country Link
US (2) US10800734B2 (https=)
JP (2) JP6884800B2 (https=)
CN (2) CN109152752A (https=)
WO (1) WO2017193870A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662216A (zh) * 2019-03-05 2020-09-15 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型及其制备方法
WO2021073548A1 (zh) * 2019-10-16 2021-04-22 广东东阳光药业有限公司 一种药物组合物
CN115925584A (zh) * 2021-08-27 2023-04-07 广东东阳光药业有限公司 一种取代的金刚烷胺类化合物的结晶方法
WO2024012565A1 (zh) * 2022-07-15 2024-01-18 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途
WO2025011640A1 (zh) * 2023-07-13 2025-01-16 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10800734B2 (en) * 2016-05-07 2020-10-13 Sunshine Lake Pharma Co., Ltd. Memantine compounds and their preparation and uses thereof
CN109959731B (zh) * 2017-12-26 2022-07-08 广东东阳光药业有限公司 一种用hplc法测定美金刚衍生物的方法
CN110433131B (zh) * 2018-05-03 2024-09-03 广东东阳光药业股份有限公司 一种药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634859A (zh) * 2004-10-28 2005-07-06 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
US20150210712A1 (en) * 2011-12-15 2015-07-30 Alkermes Pharma Ireland Limited Prodrugs of Secondary Amine Compounds
WO2017035733A1 (zh) * 2015-08-31 2017-03-09 深圳青雅启瑞生物科技有限公司 美金刚与牛蒡子苷元的缀合物及其组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
JP2010026942A (ja) * 2008-07-23 2010-02-04 Hitachi Ltd 情報処理システム
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
CN103553932B (zh) 2013-11-12 2015-03-25 江苏正大清江制药有限公司 一种适合工业化制备盐酸美金刚的方法
US10800734B2 (en) * 2016-05-07 2020-10-13 Sunshine Lake Pharma Co., Ltd. Memantine compounds and their preparation and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1634859A (zh) * 2004-10-28 2005-07-06 中国医学科学院医药生物技术研究所 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用
US20150210712A1 (en) * 2011-12-15 2015-07-30 Alkermes Pharma Ireland Limited Prodrugs of Secondary Amine Compounds
WO2017035733A1 (zh) * 2015-08-31 2017-03-09 深圳青雅启瑞生物科技有限公司 美金刚与牛蒡子苷元的缀合物及其组合物和用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662216A (zh) * 2019-03-05 2020-09-15 广东东阳光药业有限公司 一种金刚烷胺类化合物的晶型及其制备方法
WO2021073548A1 (zh) * 2019-10-16 2021-04-22 广东东阳光药业有限公司 一种药物组合物
CN115925584A (zh) * 2021-08-27 2023-04-07 广东东阳光药业有限公司 一种取代的金刚烷胺类化合物的结晶方法
WO2024012565A1 (zh) * 2022-07-15 2024-01-18 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途
WO2025011640A1 (zh) * 2023-07-13 2025-01-16 广州市恒诺康医药科技有限公司 美金刚衍生物、其药物组合物及其用途

Also Published As

Publication number Publication date
US10800734B2 (en) 2020-10-13
JP6884800B2 (ja) 2021-06-09
US20190144378A1 (en) 2019-05-16
CN113336673A (zh) 2021-09-03
JP2019521958A (ja) 2019-08-08
US20200399208A1 (en) 2020-12-24
WO2017193870A1 (en) 2017-11-16
JP2021119163A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
CN109152752A (zh) 一种金刚烷胺类化合物及其制备方法和用途
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
US8969588B2 (en) Solid forms of an antiviral compound
CN115368373A (zh) 螺环类化合物及其用途
WO2024217557A1 (zh) 取代的四氢呋喃作为Nav1.8抑制剂
CA3211820A1 (en) Isoquinolone compound and use thereof
CA3137091A1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
ES2927352T3 (es) Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos
WO2021213317A1 (zh) Hpk1抑制剂及其制备方法和用途
EP4089088A1 (en) Mor receptor agonist compound, preparation method therefor, and use thereof
CN112888479A (zh) 用于治疗病态状况的芳香型分子
CA3194087A1 (en) Benzamide compound and use thereof
TW202328122A (zh) 降解Bcl-2家族蛋白的化合物及其在醫藥上的應用
EP3950677A1 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
IL298941A (en) Heterocyclic compounds and imaging agents for the imaging of huntingtin protein
WO2025103489A1 (zh) 一种hpk1降解剂及其在医药上的应用
AU2020320034A1 (en) Inhibitors of human ATGL
US20240228467A1 (en) Indirubin compounds and methods thereof
US20190092756A1 (en) Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
WO2019203951A1 (en) Selective potassium channel agonists
WO2025067360A1 (zh) 一种DGKzeta拮抗剂及其在医药上的应用
WO2025256572A1 (zh) 一种Nav1.8抑制剂及其在医药上的应用
WO2023116527A1 (zh) 作为fak抑制剂的化合物及其用途
TW202309050A (zh) 用於亨丁頓（ｈｕｎｔｉｎｇｔｉｎ）蛋白造影之氘化化合物及造影劑
EA053131B1 (ru) Соединения изоиндолинона и визуализирующие агенты для визуализации белка хантингтина

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190104

RJ01 Rejection of invention patent application after publication